about
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsHematopoietic stem cell transplantation: a global perspectiveHaploidentical Stem Cell Transplantation in Adult Haematological MalignanciesChronic myeloid leukemia: reminiscences and dreamsWhere is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species?Gene therapy on the moveCommonly used mesenchymal stem cell markers and tracking labels: Limitations and challengesGraft-versus-host disease: why have we not made more progress?The EBMT activity survey: 1990-2010Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases.Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm.Diabetes impairs hematopoietic stem cell mobilization by altering niche function.Hematopoietic SCT in Europe: data and trends in 2011.[Authorization of tissue and blood stem cell preparations for hematopoietic reconstitution: Documentation of clinical and nonclinical data in a central expert report].Phenotypic evolutionary models in stem cell biology: replacement, quiescence, and variabilityLosing the genetic twin: donor grief after unsuccessful unrelated stem cell transplantation.Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantationLong-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantationUse of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.Transplantation immunology: solid organ and bone marrow.High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine.Support of unrelated stem cell donor searches by donor center-initiated HLA typing of potentially matching donors.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Regenerative medicine. Opportunities and challenges: a brief overviewα-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.Concise review: umbilical cord blood transplantation: past, present, and futureThe Impact of the German Tissue Act on the Manufacturing of Autologous and Allogeneic Stem Cell PreparationsThe ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.High-dose cyclophosphamide for graft-versus-host disease prevention.Examining the feasibility of clinical grade CD271+ enrichment of mesenchymal stromal cells for bone regeneration.Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of thAlpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion.Vision-Related Quality of Life in Patients with Ocular Graft-versus-Host Disease.
P2860
Q24195048-AE44CA23-4DA6-4DE8-B0AF-7F69F62EBBE2Q24624697-B07F6E41-0BAB-4FEB-A1AA-F5800286FFCBQ26745527-BD4E52A8-A1BC-4807-A393-D125F96A8E41Q26748769-46EBB3B7-79FE-4F1B-B933-F8ED232C612DQ26797474-4CBE930D-6B64-45C0-9BC7-1021A10726F0Q27007012-C5DDC5BF-4F87-4CA0-AF7D-FC87B86CAD66Q27008622-C5E9C034-CDB9-4DD8-959F-BBD017EF1488Q27012940-F77D1FAE-6126-45F0-8490-238144551E25Q28265604-861C6569-D662-4F86-A972-701CCBD62B0DQ30401036-A700E299-7387-4339-9D88-B7679299B7A6Q30536417-024C82D8-8636-43EC-9FCD-01999F088007Q30543776-BDD069B7-22CD-48B7-B642-1006DB9B1CD1Q30616418-0C88E4BC-94AB-447D-BC64-A208B61DF5CAQ31004560-2990F96F-DEB9-48B3-ABA8-FA787A1402C1Q33319567-D4B43C74-0DB5-44B0-B396-F3D42766E1D9Q33398146-2143048A-73F6-4CD4-9670-861AF5ED75F5Q33416874-A4209C94-B089-4999-A045-0EEC86121C16Q33558733-05078DA5-201D-4BB6-953E-1FC88452F131Q33634455-FDDDA1D5-A558-43EB-8B2C-DDB8BF43A70DQ33733022-26D096B2-335C-4BE7-9CA6-4DFA6CDF3660Q33786536-29298341-AF05-4F81-AF33-148DFDDBE396Q33803804-B221384B-E5A2-4ABD-87B5-4B0669B68919Q33806054-50B89211-0C99-49CB-A50D-96C4D5E117A6Q33873772-6EB2B86D-8EF0-4772-9B6B-4DAF94B8E75DQ33916233-A3589C01-A306-4676-AFF6-C2D1C95B20F1Q34293038-147F4B33-7E1F-4C32-904C-ED84D8BAA1FDQ34333343-74AF0EFF-07C9-4F2F-8033-1AA46650A06EQ34431458-0ACDE725-979F-4A25-A905-CF95C92D8F5FQ34463419-27275F52-DA17-4BE5-B1DC-4A8685DFCBF6Q34601968-EF6E8314-59E1-4932-8151-F6B1EDF9CB03Q34803990-8990C5AD-942F-4B68-9B84-B7F9D686E6D4Q35041174-24087DA9-4F6D-4D4A-A87E-F4C8FE199F4DQ35110765-3A67B299-4A56-492F-9B23-23FA5ADA189FQ35168406-EA51326E-E006-4D15-899F-75830EE8A721Q35288778-4BF1117B-79CF-4AA1-8C0C-B5DEF6684DC4Q35586590-248E394D-46F8-4171-ADD3-C56C6539FC4CQ35673668-D3BEE900-4637-4DF7-B850-01ADF2FA9330Q35865094-5725ED3A-94D9-4E4C-99D7-BC51DFDA2ECEQ35872695-CB30B06A-8EA0-4435-A912-D7EBCA47CAE1Q35894005-A813C0A1-733F-42D2-8B98-01AD1B01910C
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Hematopoietic-cell transplantation at 50.
@en
Hematopoietic-cell transplantation at 50.
@nl
type
label
Hematopoietic-cell transplantation at 50.
@en
Hematopoietic-cell transplantation at 50.
@nl
prefLabel
Hematopoietic-cell transplantation at 50.
@en
Hematopoietic-cell transplantation at 50.
@nl
P356
P1476
Hematopoietic-cell transplantation at 50.
@en
P304
P356
10.1056/NEJMP078166
P407
P577
2007-10-01T00:00:00Z